AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.415
+0.105 (4.55%)
Jun 4, 2025, 1:53 PM - Market open
AbCellera Biologics Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for AbCellera Biologics stock ranges from a low of $5.00 to a high of $10. The average analyst price target of $8.33 forecasts a 244.93% increase in the stock price over the next year.
Price Target: $8.33 (+244.93%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $28 → $10 | Strong Buy | Maintains | $28 → $10 | +314.08% | May 16, 2025 |
| Keybanc | Keybanc | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +107.04% | Apr 16, 2025 |
| Benchmark | Benchmark | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 3, 2025 |
| Stifel | Stifel | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +314.08% | Feb 28, 2025 |
| Keybanc | Keybanc | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +65.63% | Jan 8, 2025 |
Financial Forecast
Revenue This Year
25.63M
from 28.83M
Decreased by -11.12%
Revenue Next Year
35.01M
from 25.63M
Increased by 36.62%
EPS This Year
-0.66
from -0.55
EPS Next Year
-0.66
from -0.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 52.5M | 63.0M | 72.5M | ||
| Avg | 25.6M | 35.0M | 46.9M | ||
| Low | 17.4M | 22.5M | 30.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 82.1% | 145.8% | 106.9% | ||
| Avg | -11.1% | 36.6% | 34.0% | ||
| Low | -39.5% | -12.0% | -13.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.60 | -0.41 | -0.59 | ||
| Avg | -0.66 | -0.66 | -0.73 | ||
| Low | -0.74 | -0.79 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.